Bupivacaine-d9

Bupivacaine-d99 is a deuterium labeled Bupivacaine. Bupivacaine is a NMDA receptor inhibitor.Bupivacaine can block sodium, L-calcium, and potassium channels.Bupivacaine potently blocks SCN5A channels with the IC50 of 69.5 μM. Bupivacaine can be used for the research of chronic pain[1][2][3].

Product Specifications

CAS Number

[474668-57-0]

UNSPSC

12352005

Hazard Statement

H300, H310, H330

Target

Calcium Channel; iGluR; Isotope-Labeled Compounds; Potassium Channel; Sodium Channel

Type

Isotope-Labeled Compounds

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling; Others

Field of Research

Neurological Disease

Purity

99.04

Solubility

DMSO : 100 mg/mL (ultrasonic; warming)

Smiles

CC1=CC=CC(C)=C1NC(C2N(CCCC2)C([2H])(C([2H])(C([2H])(C([2H])([2H])[2H])[2H])[2H])[2H])=O

Molecular Formula

C18H19D9N2O

Molecular Weight

297.48

Precautions

H300, H310, H330

References & Citations

[1]Stoetzer C, et al. Inhibition of Voltage-Gated Na+ Channels by Bupivacaine Is Enhanced by the Adjuvants Buprenorphine, Ketamine, and Clonidine. Reg Anesth Pain Med. 2017;42 (4) :462-468.|[2]Schwoerer AP, et al. A Comparative Analysis of Bupivacaine and Ropivacaine Effects on Human Cardiac SCN5A Channels. Anesth Analg. 2015;120 (6) :1226-1234.|[3]Paganelli MA, et al. Actions of bupivacaine, a widely used local anesthetic, on NMDA receptor responses. J Neurosci. 2015;35 (2) :831-842.